Book Cover
Home  |   Healthcare   |  Immuno-oncology Drugs Market

Immuno-oncology Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy), By Application (Hospitals, Pharmacies, Online Pharmacies), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Detailed TOC of Global Immuno-oncology Drugs Market Trends Analysis Report 2026, Forecast to 2035

Table of Content

1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Immuno-oncology Drugs Market Size
1.3 Market Segmentation
1.4 Regulatory Environment

2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Immuno-oncology Drugs Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Immuno-oncology Drugs Business Mode and Production Process
2.3.1 Immuno-oncology Drugs Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Immuno-oncology Drugs Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Immuno-oncology Drugs
2.4.2 Raw Material Cost of Immuno-oncology Drugs
2.4.3 Labor Cost of Immuno-oncology Drugs
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis

3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 The Impact of Regional Situation on ${Immuno-oncology Drugs} Industries
3.7 The Impact of Inflation on ${Immuno-oncology Drugs} Industries
3.8 The Transformative Power of AI on ${Immuno-oncology Drugs} Industries
3.9 Economic Development in an Era of Climate Change
3.10 The Impact of U.S. Reciprocal Tariffs on the Industry
3.10.1 Supply Chain Alternatives Analysis
3.10.2 Region-wise Consumer Behavior Analysis
3.10.3 Price-sensitive Market Trends Analysis
3.10.4 Analysis of Changes in Competitive Landscape
3.10.5 Strategies for Businesses Addressing Tariff Changes
3.10.6 Analysis on Investment Trend

4 Market Competitive Landscape
4.1 Global Immuno-oncology Drugs Revenue and Market Share by Manufacturer (2021-2026)
4.2 Global Immuno-oncology Drugs Sales Volume and Market Share by Manufacturer (2021-2026)
4.3 Global Immuno-oncology Drugs Price by Manufacturer (2021-2026)
4.4 Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Immuno-oncology Drugs, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Immuno-oncology Drugs, Product Offered and Application
4.7 Immuno-oncology Drugs Market Competitive Situation and Trends
4.7.1 Immuno-oncology Drugs Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Immuno-oncology Drugs Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans

5 Global Immuno-oncology Drugs Market Historical Development by Geographic Region (2021-2026)
5.1 Global Immuno-oncology Drugs Market Historical Sales Volume by Geographic Region (2021-2026)
5.2 Global Immuno-oncology Drugs Market Historical Revenue by Geographic Region (2021-2026)
5.3 North America Immuno-oncology Drugs Market Status by Country (2021-2026)
5.3.1 North America Immuno-oncology Drugs Sales Volume by Country (2021-2026)
5.3.2 North America Immuno-oncology Drugs Revenue by Country (2021-2026)
5.3.3 United States Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.3.4 Canada Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4 Europe Immuno-oncology Drugs Market Status by Country (2021-2026)
5.4.1 Europe Immuno-oncology Drugs Sales Volume by Country (2021-2026)
5.4.2 Europe Immuno-oncology Drugs Revenue by Country (2021-2026)
5.4.3 Germany Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4.4 France Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4.5 United Kingdom Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4.6 Spain Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4.7 Russia Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.4.8 Poland Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5 Asia Pacific Immuno-oncology Drugs Market Status by Country (2021-2026)
5.5.1 Asia Pacific Immuno-oncology Drugs Sales Volume by Country (2021-2026)
5.5.2 Asia Pacific Immuno-oncology Drugs Revenue by Country (2021-2026)
5.5.3 China Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5.4 Japan Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5.5 South Korea Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5.6 Southeast Asia Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5.7 India Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.5.8 Australia Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.6 Latin America Immuno-oncology Drugs Market Status by Country (2021-2026)
5.6.1 Latin America Immuno-oncology Drugs Sales Volume by Country (2021-2026)
5.6.2 Latin America Immuno-oncology Drugs Revenue by Country (2021-2026)
5.6.3 Mexico Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.6.4 Brazil Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.7 Middle East and Africa Immuno-oncology Drugs Market Status by Country (2021-2026)
5.7.1 Middle East and Africa Immuno-oncology Drugs Sales Volume by Country (2021-2026)
5.7.2 Middle East and Africa Immuno-oncology Drugs Revenue by Country (2021-2026)
5.7.3 GCC Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)
5.7.4 South Africa Immuno-oncology Drugs Sales Volume, Revenue and Growth (2021-2026)

6 Global Immuno-oncology Drugs Market Historical Development by Product Type (2021-2026)
6.1 Immuno-oncology Drugs Definition by Type
6.2 Global Immuno-oncology Drugs Historical Sales Volume by Product Type (2021-2026)
6.3 Global Immuno-oncology Drugs Historical Revenue by Product Type (2021-2026)
6.4 Global Immuno-oncology Drugs Historical Price by Product Type (2021-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2021-2026)
6.5.1 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Immune Checkpoint Inhibitors (2021-2026)
6.5.2 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Monoclonal Antibodies (2021-2026)
6.5.3 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Cytokine-Based Immunotherapy (2021-2026)
6.5.4 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Cancer Vaccines (2021-2026)
6.5.5 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of CAR-T Cell Therapy (2021-2026)

7 Global Immuno-oncology Drugs Market Historical Development by End User (2021-2026)
7.1 Downstream Market Overview
7.2 Global Immuno-oncology Drugs Historical Sales Volume by End User (2021-2026)
7.3 Global Immuno-oncology Drugs Historical Revenue by End User (2021-2026)
7.4 Global Immuno-oncology Drugs Historical Price by End User (2021-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2021-2026)
7.5.1 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Hospitals (2021-2026)
7.5.2 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Pharmacies (2021-2026)
7.5.3 Global Immuno-oncology Drugs Historical Sales Volume, Revenue and Growth Rate of Online Pharmacies (2021-2026)

8 Leading Companies Profiles
8.1 Aduro BioTech
8.1.1 Aduro BioTech Corporation Information
8.1.2 Aduro BioTech - Immuno-oncology Drugs Product Portfolio and Specification
8.1.3 Aduro BioTech Performance Analysis (2021-2026)
8.1.4 Aduro BioTech Business and Markets Served
8.1.5 Aduro BioTech Recent Developments
8.2 AbbVie, Inc.
8.2.1 AbbVie, Inc. Corporation Information
8.2.2 AbbVie, Inc. - Immuno-oncology Drugs Product Portfolio and Specification
8.2.3 AbbVie, Inc. Performance Analysis (2021-2026)
8.2.4 AbbVie, Inc. Business and Markets Served
8.2.5 AbbVie, Inc. Recent Developments
8.3 Galena Biopharma
8.3.1 Galena Biopharma Corporation Information
8.3.2 Galena Biopharma - Immuno-oncology Drugs Product Portfolio and Specification
8.3.3 Galena Biopharma Performance Analysis (2021-2026)
8.3.4 Galena Biopharma Business and Markets Served
8.3.5 Galena Biopharma Recent Developments
8.4 Gilead Sciences Inc.
8.4.1 Gilead Sciences Inc. Corporation Information
8.4.2 Gilead Sciences Inc. - Immuno-oncology Drugs Product Portfolio and Specification
8.4.3 Gilead Sciences Inc. Performance Analysis (2021-2026)
8.4.4 Gilead Sciences Inc. Business and Markets Served
8.4.5 Gilead Sciences Inc. Recent Developments
8.5 Prometheus Therapeutics & Diagnostics
8.5.1 Prometheus Therapeutics & Diagnostics Corporation Information
8.5.2 Prometheus Therapeutics & Diagnostics - Immuno-oncology Drugs Product Portfolio and Specification
8.5.3 Prometheus Therapeutics & Diagnostics Performance Analysis (2021-2026)
8.5.4 Prometheus Therapeutics & Diagnostics Business and Markets Served
8.5.5 Prometheus Therapeutics & Diagnostics Recent Developments
8.6 ImmunoCellular Therapeutics
8.6.1 ImmunoCellular Therapeutics Corporation Information
8.6.2 ImmunoCellular Therapeutics - Immuno-oncology Drugs Product Portfolio and Specification
8.6.3 ImmunoCellular Therapeutics Performance Analysis (2021-2026)
8.6.4 ImmunoCellular Therapeutics Business and Markets Served
8.6.5 ImmunoCellular Therapeutics Recent Developments
8.7 Merck & Co.
8.7.1 Merck & Co. Corporation Information
8.7.2 Merck & Co. - Immuno-oncology Drugs Product Portfolio and Specification
8.7.3 Merck & Co. Performance Analysis (2021-2026)
8.7.4 Merck & Co. Business and Markets Served
8.7.5 Merck & Co. Recent Developments
8.8 Celldex Therapeutics
8.8.1 Celldex Therapeutics Corporation Information
8.8.2 Celldex Therapeutics - Immuno-oncology Drugs Product Portfolio and Specification
8.8.3 Celldex Therapeutics Performance Analysis (2021-2026)
8.8.4 Celldex Therapeutics Business and Markets Served
8.8.5 Celldex Therapeutics Recent Developments
8.9 Amgen, Inc
8.9.1 Amgen, Inc Corporation Information
8.9.2 Amgen, Inc - Immuno-oncology Drugs Product Portfolio and Specification
8.9.3 Amgen, Inc Performance Analysis (2021-2026)
8.9.4 Amgen, Inc Business and Markets Served
8.9.5 Amgen, Inc Recent Developments
8.10 Pfizer Inc.
8.10.1 Pfizer Inc. Corporation Information
8.10.2 Pfizer Inc. - Immuno-oncology Drugs Product Portfolio and Specification
8.10.3 Pfizer Inc. Performance Analysis (2021-2026)
8.10.4 Pfizer Inc. Business and Markets Served
8.10.5 Pfizer Inc. Recent Developments
8.11 Sanofi S.A.
8.11.1 Sanofi S.A. Corporation Information
8.11.2 Sanofi S.A. - Immuno-oncology Drugs Product Portfolio and Specification
8.11.3 Sanofi S.A. Performance Analysis (2021-2026)
8.11.4 Sanofi S.A. Business and Markets Served
8.11.5 Sanofi S.A. Recent Developments
8.12 Eli Lilly and Company
8.12.1 Eli Lilly and Company Corporation Information
8.12.2 Eli Lilly and Company - Immuno-oncology Drugs Product Portfolio and Specification
8.12.3 Eli Lilly and Company Performance Analysis (2021-2026)
8.12.4 Eli Lilly and Company Business and Markets Served
8.12.5 Eli Lilly and Company Recent Developments
8.13 Hoffmann-La Roche AG
8.13.1 Hoffmann-La Roche AG Corporation Information
8.13.2 Hoffmann-La Roche AG - Immuno-oncology Drugs Product Portfolio and Specification
8.13.3 Hoffmann-La Roche AG Performance Analysis (2021-2026)
8.13.4 Hoffmann-La Roche AG Business and Markets Served
8.13.5 Hoffmann-La Roche AG Recent Developments
8.14 Bavarian Nordic
8.14.1 Bavarian Nordic Corporation Information
8.14.2 Bavarian Nordic - Immuno-oncology Drugs Product Portfolio and Specification
8.14.3 Bavarian Nordic Performance Analysis (2021-2026)
8.14.4 Bavarian Nordic Business and Markets Served
8.14.5 Bavarian Nordic Recent Developments
8.15 Johnson & Johnson
8.15.1 Johnson & Johnson Corporation Information
8.15.2 Johnson & Johnson - Immuno-oncology Drugs Product Portfolio and Specification
8.15.3 Johnson & Johnson Performance Analysis (2021-2026)
8.15.4 Johnson & Johnson Business and Markets Served
8.15.5 Johnson & Johnson Recent Developments
8.16 Bristol-Myers Squibb
8.16.1 Bristol-Myers Squibb Corporation Information
8.16.2 Bristol-Myers Squibb - Immuno-oncology Drugs Product Portfolio and Specification
8.16.3 Bristol-Myers Squibb Performance Analysis (2021-2026)
8.16.4 Bristol-Myers Squibb Business and Markets Served
8.16.5 Bristol-Myers Squibb Recent Developments
8.17 AstraZeneca, Plc
8.17.1 AstraZeneca, Plc Corporation Information
8.17.2 AstraZeneca, Plc - Immuno-oncology Drugs Product Portfolio and Specification
8.17.3 AstraZeneca, Plc Performance Analysis (2021-2026)
8.17.4 AstraZeneca, Plc Business and Markets Served
8.17.5 AstraZeneca, Plc Recent Developments
8.18 Celgene Corporation
8.18.1 Celgene Corporation Corporation Information
8.18.2 Celgene Corporation - Immuno-oncology Drugs Product Portfolio and Specification
8.18.3 Celgene Corporation Performance Analysis (2021-2026)
8.18.4 Celgene Corporation Business and Markets Served
8.18.5 Celgene Corporation Recent Developments
8.19 Novartis International AG
8.19.1 Novartis International AG Corporation Information
8.19.2 Novartis International AG - Immuno-oncology Drugs Product Portfolio and Specification
8.19.3 Novartis International AG Performance Analysis (2021-2026)
8.19.4 Novartis International AG Business and Markets Served
8.19.5 Novartis International AG Recent Developments
8.20 EMD Serono, Inc.
8.20.1 EMD Serono, Inc. Corporation Information
8.20.2 EMD Serono, Inc. - Immuno-oncology Drugs Product Portfolio and Specification
8.20.3 EMD Serono, Inc. Performance Analysis (2021-2026)
8.20.4 EMD Serono, Inc. Business and Markets Served
8.20.5 EMD Serono, Inc. Recent Developments
8.21 Incyte
8.21.1 Incyte Corporation Information
8.21.2 Incyte - Immuno-oncology Drugs Product Portfolio and Specification
8.21.3 Incyte Performance Analysis (2021-2026)
8.21.4 Incyte Business and Markets Served
8.21.5 Incyte Recent Developments

9 Global Immuno-oncology Drugs Market Forecast by Product Type and End User (2026-2035)
9.1 Global Immuno-oncology Drugs Market Forecast by Product Type (2026-2035)
9.1.1 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Immune Checkpoint Inhibitors (2026-2035)
9.1.2 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Monoclonal Antibodies (2026-2035)
9.1.3 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Cytokine-Based Immunotherapy (2026-2035)
9.1.4 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Cancer Vaccines (2026-2035)
9.1.5 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of CAR-T Cell Therapy (2026-2035)
9.2 Global Immuno-oncology Drugs Market Forecast by End User (2026-2035)
9.2.1 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Hospitals (2026-2035)
9.2.2 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Pharmacies (2026-2035)
9.2.3 Global Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth Rate of Online Pharmacies (2026-2035)

10 Global Immuno-oncology Drugs Market Forecast by Geographic Region (2026-2035)
10.1 Global Immuno-oncology Drugs Sales Volume and Revenue Forecast by Geographic Region (2026-2035)
10.2 North America Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.2.1 United States Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.2.2 Canada Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3 Europe Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.1 Germany Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.2 France Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.3 United Kingdom Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.4 Spain Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.5 Russia Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.3.6 Poland Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4 Asia Pacific Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.1 China Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.2 Japan Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.3 South Korea Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.4 Southeast Asia Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.5 India Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.4.6 Australia Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.5 Latin America Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.5.1 Mexico Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.5.2 Brazil Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.6 Middle East and Africa Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.6.1 GCC Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)
10.6.2 South Africa Immuno-oncology Drugs Sales Volume, Revenue Forecast and Growth (2026-2035)

11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer
 
Captcha refresh

Trusted & Certified

Our Clients